| P2093 | author name string | Kevin Marsh | |
| | Arman Altincatal | |
| | Ali Cimen | |
| | Richard Lawson | |
| | Frederic King | |
| P2860 | cites work | Constipation in advanced cancer patients | Q40847457 |
| | QALYs and mental health care. | Q41363863 |
| | Naloxegol for opioid-induced constipation in patients with noncancer pain | Q43318363 |
| | The Direct and Indirect Costs of Opioid-Induced Constipation | Q43630745 |
| | Chronic pain in Canada--prevalence, treatment, impact and the role of opioid analgesia | Q44272258 |
| | The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1). | Q44339922 |
| | Quality of life in relation to constipation among opioid users | Q44345358 |
| | The prevalence, correlates and treatment of pain in the European Union | Q44990528 |
| | Health-related quality of life among breast, prostate, and colorectal cancer patients with end-stage disease | Q48142261 |
| | Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1). | Q48315834 |
| | Catalogue of EQ-5D scores for the United Kingdom. | Q51047193 |
| | Should QALYs be programme-specific? | Q52069354 |
| | A comparison of the EQ-5D and SF-6D across seven patient groups | Q60629828 |
| | Presence and severity of constipation in hospice patients with advanced cancer | Q78547417 |
| | Evaluation of quality of life and priorities of patients with glaucoma | Q81152952 |
| | Cost-effectiveness analysis in glaucoma: what drives utility? Results from a pilot study in Sweden | Q83355857 |
| | Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden | Q28209970 |
| | Survey of chronic pain in Europe: Prevalence, impact on daily life, and treatment | Q30458126 |
| | Development of opioid-induced constipation: post hoc analysis of data from a 12-week prospective, open-label, blinded-endpoint streamlined study in low-back pain patients treated with prolonged-release WHO step III opioids | Q30989361 |
| | Opioid-induced constipation in patients with chronic noncancer pain in the USA, Canada, Germany, and the UK: descriptive analysis of baseline patient-reported outcomes and retrospective chart review | Q33461841 |
| | A checklist for judging preference-based measures of health related quality of life: learning from psychometrics | Q33542556 |
| | Epidemiology of chronic non-cancer pain in Europe: narrative review of prevalence, pain treatments and pain impact. | Q33782734 |
| | The Prevalence of Chronic Pain in United States Adults: Results of an Internet-Based Survey | Q34134400 |
| | A comparison of the sensitivity of EQ-5D, SF-6D and TTO utility values to changes in vision and perceived visual function in patients with primary open-angle glaucoma. | Q34386849 |
| | Development and validation of the Patient Assessment of Constipation Quality of Life questionnaire | Q34435916 |
| | A population-based survey of chronic pain and its treatment with prescription drugs | Q34627549 |
| | Patient preferences for change in symptoms associated with opioid-induced constipation | Q34737112 |
| | Quality of life and healthcare resource in patients receiving opioids for chronic pain: a review of the place of oxycodone/naloxone | Q34798408 |
| | Long-term safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate-to-severe chronic cancer pain | Q35028902 |
| | Health-related quality of life in patients with metastatic colorectal cancer treated with panitumumab in first- or second-line treatment | Q35623078 |
| | Efficacy and safety of naloxegol in patients with opioid-induced constipation and laxative-inadequate response | Q36223541 |
| | Chronic pain in Canada: have we improved our management of chronic noncancer pain? | Q37162638 |
| | Quality of life after TIA and stroke: ten-year results of the Oxford Vascular Study | Q37251654 |
| | New approaches to the treatment of opioid-induced constipation. | Q37299608 |
| | The role of opioids in managing chronic non-cancer pain | Q37643481 |
| | Pharmacoeconomic Impact of Adverse Events of Long-Term Opioid Treatment for the Management of Persistent Pain | Q37808457 |
| | Opioid-induced constipation: challenges and therapeutic opportunities | Q37846099 |
| | Opioid-induced bowel dysfunction: pathophysiology and management | Q38040843 |
| | The minimum clinically important difference for EQ-5D index: a critical review | Q38195640 |
| | Longer term clinical and economic benefits of offering acupuncture care to patients with chronic low back pain | Q39363375 |
| | A qualitative study to explore psychological distress and illness burden associated with opioid-induced constipation in cancer patients with advanced disease | Q39601114 |
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | constipation | Q178436 |
| | opioid | Q427523 |
| | naloxegol | Q15708351 |
| P304 | page(s) | 1331-1346 | |
| P577 | publication date | 2016-06-24 | |
| P1433 | published in | Advances in Therapy | Q4686392 |
| P1476 | title | Impact of Treatment with Naloxegol for Opioid-Induced Constipation on Patients' Health State Utility | |
| P478 | volume | 33 | |